KR102903997B1 - UDP 글리코실트랜스퍼라제 억제제로서의 티에노[3,2-b]피리딘 유도체 및 사용 방법 - Google Patents

UDP 글리코실트랜스퍼라제 억제제로서의 티에노[3,2-b]피리딘 유도체 및 사용 방법

Info

Publication number
KR102903997B1
KR102903997B1 KR1020217013167A KR20217013167A KR102903997B1 KR 102903997 B1 KR102903997 B1 KR 102903997B1 KR 1020217013167 A KR1020217013167 A KR 1020217013167A KR 20217013167 A KR20217013167 A KR 20217013167A KR 102903997 B1 KR102903997 B1 KR 102903997B1
Authority
KR
South Korea
Prior art keywords
thieno
trifluoromethyl
pyridin
methylcarbamoyl
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020217013167A
Other languages
English (en)
Korean (ko)
Other versions
KR20210087033A (ko
Inventor
성택 임
로버트 에이치. 바커 주니어
메리 에이. 크롬웰
엘리나 마키노
브래드포드 허스
존 지앙
사친 마니아
마크 먼슨
영-미 최
수칸티니 투라이라트남
권 욘 머식
제임스 프리비쉬
마이클 안젤라스트로
Original Assignee
젠자임 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 젠자임 코포레이션 filed Critical 젠자임 코포레이션
Publication of KR20210087033A publication Critical patent/KR20210087033A/ko
Application granted granted Critical
Publication of KR102903997B1 publication Critical patent/KR102903997B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020217013167A 2018-10-01 2019-10-01 UDP 글리코실트랜스퍼라제 억제제로서의 티에노[3,2-b]피리딘 유도체 및 사용 방법 Active KR102903997B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862739405P 2018-10-01 2018-10-01
US62/739,405 2018-10-01
PCT/US2019/054085 WO2020072504A1 (en) 2018-10-01 2019-10-01 Thieno[3,2-b]pyridine derivatives as udp glycosyltransferase inhibitors and methods of use

Publications (2)

Publication Number Publication Date
KR20210087033A KR20210087033A (ko) 2021-07-09
KR102903997B1 true KR102903997B1 (ko) 2025-12-26

Family

ID=68296740

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217013167A Active KR102903997B1 (ko) 2018-10-01 2019-10-01 UDP 글리코실트랜스퍼라제 억제제로서의 티에노[3,2-b]피리딘 유도체 및 사용 방법

Country Status (15)

Country Link
US (1) US11098056B2 (https=)
EP (1) EP3861000A1 (https=)
JP (1) JP7545979B2 (https=)
KR (1) KR102903997B1 (https=)
CN (1) CN113423711B (https=)
AU (1) AU2019355870B2 (https=)
BR (1) BR112021005914A2 (https=)
CA (1) CA3114722A1 (https=)
CO (1) CO2021005738A2 (https=)
IL (1) IL281811B2 (https=)
MA (1) MA53043B2 (https=)
MX (1) MX2021003794A (https=)
SG (1) SG11202102987VA (https=)
TW (1) TWI821426B (https=)
WO (1) WO2020072504A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202302565A (zh) * 2021-02-19 2023-01-16 英商卡爾維斯塔製藥有限公司 酶抑制劑
EP4483954A1 (en) * 2023-06-29 2025-01-01 Masarykova Univerzita Substituted thieno [3,2-b]pyridines as inhibitors of protein kinases

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003528810A (ja) 1999-08-04 2003-09-30 ミレニアム ファーマスーティカルズ インク メラノコルチン−４受容体結合化合物及びその使用方法
JP2011503115A (ja) 2007-11-15 2011-01-27 ワイエム・バイオサイエンシズ・オーストラリア・ピーティーワイ・リミテッド Ｎ含有複素環式化合物
WO2017112777A1 (en) 2015-12-22 2017-06-29 SHY Therapeutics LLC Compounds for the treatment of cancer and inflammatory disease
WO2017192930A1 (en) * 2016-05-05 2017-11-09 Lysosomal Therapeutics Inc. SUBSTITUTED IMIDAZO[1,2-b]PYRIDAZINES, SUBSTITUTED IMIDAZO[1,5-b]PYRIDAZINES, RELATED COMPOUNDS, AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3763156A (en) * 1970-01-28 1973-10-02 Boehringer Sohn Ingelheim 2-heterocyclic amino-4-morpholinothieno(3,2-d)pyrimidines
US7375125B2 (en) * 1999-08-04 2008-05-20 Ore Pharmaceuticals, Inc. Melanocortin-4 receptor binding compounds and methods of use thereof
FR2821356A1 (fr) * 2001-02-23 2002-08-30 Cerep Nouveaux derives d'arylcarbamates et d'arylurees, preparations et utilisations
MX2011008276A (es) * 2009-02-06 2011-12-14 Elan Pharm Inc Inhibidores de quinasa jun n-terminal.
JP2014511391A (ja) * 2011-03-07 2014-05-15 フォンダッツィオーネ・テレソン Ｔｆｅｂリン酸化阻害剤およびその使用
ES2928714T3 (es) * 2015-01-16 2022-11-22 Massachusetts Gen Hospital Compuestos para mejorar el empalme del ARNm
WO2017214505A1 (en) * 2016-06-10 2017-12-14 Biomarin Pharmaceutical Inc. Ceramide galactosyltransferase inhibitors for the treatment of disease
MY193511A (en) * 2016-11-02 2022-10-17 Janssen Pharmaceutica Nv [1,2,4]triazolo[1,5-a]pyrimidine derivatives as pde2 inhibitors
WO2018118838A1 (en) * 2016-12-20 2018-06-28 Biomarin Pharmaceutical Inc. Ceramide galactosyltransferase inhibitors for the treatment of disease
EP3619209A1 (en) * 2017-05-04 2020-03-11 Glenmark Pharmaceuticals S.A. Substituted bicyclic heterocyclic compounds as nadph oxidase inhibitors
JP7514005B2 (ja) 2017-06-21 2024-07-10 シャイ・セラピューティクス・エルエルシー がん、炎症性疾患、ラソパシー、及び線維性疾患の治療のためのｒａｓスーパーファミリーと相互作用する化合物

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003528810A (ja) 1999-08-04 2003-09-30 ミレニアム ファーマスーティカルズ インク メラノコルチン−４受容体結合化合物及びその使用方法
JP2011503115A (ja) 2007-11-15 2011-01-27 ワイエム・バイオサイエンシズ・オーストラリア・ピーティーワイ・リミテッド Ｎ含有複素環式化合物
WO2017112777A1 (en) 2015-12-22 2017-06-29 SHY Therapeutics LLC Compounds for the treatment of cancer and inflammatory disease
WO2017192930A1 (en) * 2016-05-05 2017-11-09 Lysosomal Therapeutics Inc. SUBSTITUTED IMIDAZO[1,2-b]PYRIDAZINES, SUBSTITUTED IMIDAZO[1,5-b]PYRIDAZINES, RELATED COMPOUNDS, AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS

Non-Patent Citations (15)

* Cited by examiner, † Cited by third party
Title
Chemical Abstract Compound, STN express. RNs: 677706-91-1
Chemical Abstract Compound, STN express. RNs: 677706-92-2
Chemical Abstract Compound, STN express. RNs: 680202-27-1
Chemical Abstract Compound, STN express. RNs: 680202-28-2
Chemical Abstract Compound, STN express. RNs: 680202-29-3
Chemical Abstract Compound, STN express. RNs: 680202-30-6
Chemical Abstract Compound, STN express. RNs: 680202-31-7
Chemical Abstract Compound, STN express. RNs: 680202-32-8
Chemical Abstract Compound, STN express. RNs: 680202-33-9
Chemical Abstract Compound, STN express. RNs: 680202-34-0
Chemical Abstract Compound, STN express. RNs: 680203-21-8
Chemical Abstract Compound, STN express. RNs: 913501-59-4
Chemical Abstract Compound, STN express. RNs: 913503-10-3
Chemical Abstract Compound, STN express. RNs: 913508-83-5
Chemical Abstract Compound, STN express. RNs: 913517-57-4

Also Published As

Publication number Publication date
IL281811B2 (en) 2025-03-01
JP2022508523A (ja) 2022-01-19
US11098056B2 (en) 2021-08-24
MX2021003794A (es) 2021-09-08
BR112021005914A2 (pt) 2021-06-29
AU2019355870B2 (en) 2023-11-16
SG11202102987VA (en) 2021-04-29
MA53043A1 (fr) 2022-08-31
TW202035419A (zh) 2020-10-01
IL281811A (en) 2021-05-31
EP3861000A1 (en) 2021-08-11
KR20210087033A (ko) 2021-07-09
AU2019355870A1 (en) 2021-05-20
CA3114722A1 (en) 2020-04-09
IL281811B1 (en) 2024-11-01
MA53043B2 (fr) 2024-05-31
CN113423711B (zh) 2024-03-15
US20200102324A1 (en) 2020-04-02
WO2020072504A1 (en) 2020-04-09
TWI821426B (zh) 2023-11-11
CN113423711A (zh) 2021-09-21
CO2021005738A2 (es) 2021-05-10
JP7545979B2 (ja) 2024-09-05

Similar Documents

Publication Publication Date Title
US11542266B1 (en) Substituted piperidines as BTK inhibitors
US9273057B2 (en) Imidazotriazinecarbonitriles useful as kinase inhibitors
KR20230028269A (ko) 헌팅턴병을 치료하기 위한 htt 조절제
JP2025519417A (ja) Ｅ３リガーゼリガンドとｉｒａｋ４阻害剤との結合によるｉｒａｋ４の分解及びその使用方法
EP2536730A1 (en) Pyrrolopyrimidine compounds as inhibitors of cdk4/6
EP3546458B1 (en) ((pyridin-2-yl)-amino)pyrido[3,4-d]pyrimidine and ((pyridazin-3-yl)-amino)pyrido[3,4-d]pyrimidine derivatives as cdk4/6 inhibitors for treating e.g. rheumatoid arthritis, arteriosclerosis, pulmonary fibrosis, cerebral infarction or cancer
US20240342292A1 (en) Compounds for the Degradation of EGFR Kinase
CN116783199A (zh) 作为btk抑制剂的吡唑并[1,5-a]吡嗪衍生物
EP3847165A1 (en) Novel pyrrolidine amine compounds for the treatment of autoimmune disease
ES3023544T3 (en) Atm kinase inhibitors and compositions and methods of use thereof
KR102903997B1 (ko) UDP 글리코실트랜스퍼라제 억제제로서의 티에노[3,2-b]피리딘 유도체 및 사용 방법
RU2810928C2 (ru) Ингибиторы уридин-5-дифосфат (udp) гликозилтрансферазы и способы их применения
TW202502750A (zh) Smarca2之雙官能選擇性降解劑及其治療用途
HK40053673B (zh) 一种btk抑制剂环衍生物及其制备方法和药学上的应用
HK40082036B (en) Atm kinase inhibitors and compositions and methods of use thereof
HK40082036A (en) Atm kinase inhibitors and compositions and methods of use thereof
HK40043697A (en) Novel pyrrolidine amine compounds for the treatment of autoimmune disease

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

U12 Designation fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

Q13 Ip right document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE)